Intervention not reported
Secondary ‐ Adverse events · Patients with acute uncomplicated diverticulitis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
117 questions · 117 findings · 44 reviews
No studies found 21 · 17.9%GRADE not reported 13 · 11.1%Very low 29 · 24.8%Low 33 · 28.2%Moderate 18 · 15.4%High 3 · 2.6%
Intervention not reported
Secondary ‐ Adverse events · Patients with acute uncomplicated diverticulitis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Ceftriaxone vs long‐acting (oily) Chloramphenicol compared
Adverse events ‐ short term · people suspected to have meningococcal disease (adults and children)
1 finding from 1 review
- Pre‐admission antibiotics for suspected cases of meningococcal disease 2017 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 1 participantsGRADE not reported
Intervention not reported
Adverse events Toxic deaths · cancer patients receiving myelotoxic chemotherapy
The intervention showed no clear difference in adverse events Toxic deaths (low certainty).
1 finding from 1 review
- Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients… 2015 · Cochrane Headline outcomes onlyRR 1.32 [0.3, 5.69]1 study · 115 participantsLow
Azithromycin vs doxycycline
Adverse events Men and women · men and non‐pregnant women with symptomatic (uterine cervicitis and urethritis), or asymptomatic genital CT infection, diagnosed by cell…
Azithromycin probably leads to lower adverse events Men and women compared with doxycycline (moderate certainty).
1 finding from 1 review
- Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non‐pregnant women 2019 · Cochrane Headline outcomes onlyRR 0.83 [0.71, 0.98]9 studies · 2261 participantsModerate
Cefepime vs ceftazidime
Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia
It is very uncertain whether cefepime changes serious adverse events Maximum compared with ceftazidime (very low certainty).
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyRR 0.14 [0.01, 2.55]1 study · 30 participantsVery low
Linezolid vs vancomycin
Serious adverse events maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Antibiotic with anti‐TNF vs placebo with anti‐TNF
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic with anti‐TNF showed no clear difference in withdrawal due to adverse events compared with placebo with anti‐TNF (low certainty).
1 finding from 1 review
- Antibiotics for induction and maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.82 [0.19, 3.45]2 studies · 100 participantsLow
Antibiotics vs placebo
Withdrawals due to adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
- Antibiotics for induction and maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.86 [0.57, 1.29]9 studies · 858 participantsLow
Continuous vs Intermittent Antibiotic Infusions
Withdrawals due to adverse events
Continuous showed no clear difference in withdrawal due to adverse events compared with intermittent Antibiotic Infusions (low certainty).
1 finding from 1 review
- Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections 2013 · Cochrane Headline outcomes onlyRR 2.03 [0.52, 7.95]10 studies · 871 participantsLow
Linezolid vs vancomycin
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Cefepime vs ceftazidime
Non‐serious adverse events Maximum · neonates and children with hospital‐acquired pneumonia
The review found no eligible studies for this question.
1 finding from 1 review
- Antibiotics for hospital‐acquired pneumonia in neonates and children 2021 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Macrolides vs no intervention
Serious adverse events ‐ not reported · children with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Macrolides vs no intervention
Serious adverse events ‐ not reported · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review
- Antibiotics for preventing lower respiratory tract infections in high‐risk children aged 12 years and under 2015 · Cochrane Headline outcomes onlyRR 1.1 [0.75, 1.64]3 studies · 1344 participantsModerate
Azithromycin vs placebo or usual care
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
- no estimate extracted0 studies · 0 participantsGRADE not reported
Azithromycin vs placebo or usual care
Adverse events during treatment period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
- RR 1.2 [0.92, 1.57]3 studies · 355 participantsLow
Azithromycin vs placebo or usual care
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
- no estimate extracted2 studies · 454 participantsVery low
Azithromycin vs placebo or usual care
Serious adverse events during the study period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in serious adverse events during the study period compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
- RR 1.11 [0.89, 1.4]4 studies · 794 participantsModerate
Oral + inhaled dual therapy vs oral monotherapy
Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
- OR 0.48 [0.08, 2.87]1 study · 53 participantsVery low